Glycoscientific Raises the Accuracy and Precision Standard for Glycan Quantitation.
Athens, GA, May 30, 2015 --(PR.com)-- GlycoScientific is pleased to introduce iGlycoMabTM, a monoclonal antibody (mAb) whose glycans are labeled with a stable isotope. This product is designed to offer the glycobiology community the accuracy and precision provided by an isotopically labeled standard, and will be highlighted by various presentations at the 2015 American Society for Mass Spectrometry (ASMS) conference.1
iGlycoMabTM is designed to facilitate quantitative glycan profiling of biological therapeutics, particularly monoclonal antibodies and fusion proteins. However, iGlycoMabTM can be applied to individual glycans or complex mixtures such as those observed in the field of glycomics. "We envision that the combination of isotopically labeled glycan with LC-MS analysis will become the new gold standard from glycan quantification," states Ron Orlando, a GlycoScientific founder.
"The use of 15N labeled N-glycans derived from IGG has alleviated quantitative MS-based glycomics variabilities originating from PNGase F digestion efficiency, chemical derivatization and ionization efficiency," states Yehia Mechref Professor in the Department of Chemistry and Biochemistry, Texas Tech University. This enables dramatic improvement of the accuracy and precision compared to other approaches and does not require modification of the user's methodology. In addition, iGlycoMabTM can be directly incorporated into mass spectrometric glycan/glycomic workflows, enabling reliable quantitative results to be obtained from qualitative discovery experiments. Furthermore, because "like molecules" will experience similar biases during the sample preparation and measurement the use of a labeled mAb is ideal for the analysis of other mAbs.
The originality and overall benefit to the scientific community were attributes that garnered an outstanding scientific presentation award at the 2015 conference of the Association of Biomolecular Resource Facilities.
iGlycoMabTM can be purchased online at www.glycoscientific.com.
GlycoScientific, LLC is a privately-held company engaged in the development and commercialization of unique research reagents in the field of glycobiology, including development of products that involve characterization of glycosylation. The company is based in Athens, Georgia, next door to the University of Georgia's Complex Carbohydrate Research Center. The company is backed by a team that is embedded in many relevant disciplines, including proteomics, glycomics, liquid chromatography and mass spectrometry of glycans and glycoproteins. GlycoScientific has received funding from the National Institutes of Health and private sources, including the Georgia Research Alliance. For more information, please visit www.glycoscientific.com.
Contact: Ron Orlando
iGlycoMab is a trademark of GlycoScientific, LLC.
1iGlycoMabTM will be highlighted in ASMS presentations MP 682 and WOD am 9:50.
Contact via Email
Read the full story here: http://www.pr.com/press-release/621763
|Printer friendly Cite/link Email Feedback|
|Publication:||PR.com (Press Releases)|
|Date:||May 30, 2015|
|Previous Article:||Texas Energy Group, LLC (TEG) Affiliate Spuds Third Well in Wharton County, TX.|
|Next Article:||Launch of ID- Digital City (shops-id.com) and CrowdMarketing Innovation by Paris HUB.|